DT Midstream enters the back half of May with the Street scrambling to keep up — five firms have raised price targets in two weeks, and the stock just printed a fresh high at $148.08.
The analyst story is the cleanest signal this week. Target upgrades have come in rapid succession since the Q1 print on April 30. UBS lifted its target to $170 (from $152) just this week while staying at Buy. Morgan Stanley followed hours later, nudging to $170 from $165. Citi raised to $169 earlier in the month, and Mizuho moved to $153 from $129 — all maintaining existing ratings rather than changing conviction, which tells you these are calibration moves after better-than-expected results rather than fresh enthusiasm. The lone dissenter remains Goldman Sachs, which kept its Sell but raised its own target to $127, still well below where the stock trades. The mean analyst target now sits at $151.71 — barely above current levels — suggesting the consensus is effectively running flat-footed after the rally.
Short positioning offers little drama. Short interest in DTM runs at 3.7% of free float, modest for an infrastructure name, and it rose roughly 4% over the past week — a drift upward rather than a conviction build. Borrow costs are cheap, sitting around 0.35% annualised and down roughly 23% over the past month. Availability in the lending pool is abundant, with borrow far from constrained. The ORTEX short score holds at 39, comfortably in the lower half of the range, reflecting a market that is not aggressively positioned against this name. Nothing in the borrow market suggests shorts are under meaningful pressure.
The bull case for DTM rests on contract security and growth visibility — a $3.4 billion organic project backlog, largely underpinned by take-or-pay structures, and management guiding for 5-7% annual dividend growth alongside EBITDA expansion. The bear case points to $3.32 billion in debt and concentrated revenue exposure to Expand Energy and the Haynesville basin. EV/EBITDA has crept up to ~14.9x on the month's run, and the PE multiple has expanded by more than three points over 30 days. The stock's dividend score ranks in the 94th percentile, and analyst recommendation divergence ranks 87th — meaning the gap between the most optimistic and most cautious analyst views is unusually wide, consistent with a stock where sentiment is genuinely split.
The recent earnings history is brief but instructive. The April 30 Q1 release drove a 6.2% one-day gain and held most of that through the following week. Two earlier events — likely prior-quarter reads — produced mild one-day declines under 2%. The pattern suggests the stock responds sharply when results beat, then fades modestly when they disappoint, though the sample is thin.
Peers have also moved sharply. WMB gained 8% on the week and TRGP was up nearly 10%, suggesting a broad midstream sector re-rating rather than a DTM-specific story. KMI added 7%. DTM's 3.7% weekly gain trails most of its closest correlates, which is worth noting given the pace of its analyst upgrades.
With no confirmed earnings date on the calendar and the mean analyst target now sitting within 2.5% of the current price, the next catalyst worth watching is whether fresh target revisions — or the absence of them — begin to shift the overall consensus distribution.
See the live data behind this article on ORTEX.
Open DTM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
